Cargando…

Why Chain Length of Hyaluronan in Eye Drops Matters

The chain length of hyaluronan (HA) determines its physical as well as its physiological properties. Results of clinical research on HA eye drops are not comparable without this parameter. In this article methods for the assessment of the average molecular weight of HA in eye drops and a terminology...

Descripción completa

Detalles Bibliográficos
Autor principal: Müller-Lierheim, Wolfgang G.K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7459843/
https://www.ncbi.nlm.nih.gov/pubmed/32717869
http://dx.doi.org/10.3390/diagnostics10080511
_version_ 1783576464056123392
author Müller-Lierheim, Wolfgang G.K.
author_facet Müller-Lierheim, Wolfgang G.K.
author_sort Müller-Lierheim, Wolfgang G.K.
collection PubMed
description The chain length of hyaluronan (HA) determines its physical as well as its physiological properties. Results of clinical research on HA eye drops are not comparable without this parameter. In this article methods for the assessment of the average molecular weight of HA in eye drops and a terminology for molecular weight ranges are proposed. The classification of HA eye drops according to their zero shear viscosity and viscosity at 1000 s(−1) shear rate is presented. Based on the gradient of mucin MUC5AC concentration within the mucoaqueous layer of the tear film a hypothesis on the consequences of this gradient on the rheological properties of the tear film is provided. The mucoadhesive properties of HA and their dependence on chain length are explained. The ability of HA to bind to receptors on the ocular epithelial cells, and in particular the potential consequences of the interaction between HA and the receptor HARE, responsible for HA endocytosis by corneal epithelial cells is discussed. The physiological function of HA in the framework of ocular surface homeostasis and wound healing are outlined, and the influence of the chain length of HA on the clinical performance of HA eye drops is illustrated. The use of very high molecular weight HA (hylan A) eye drops as drug vehicle for the next generation of ophthalmic drugs with minimized side effects is proposed and its advantages elucidated. Consequences of the diagnosis and treatment of ocular surface disease are discussed.
format Online
Article
Text
id pubmed-7459843
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74598432020-09-02 Why Chain Length of Hyaluronan in Eye Drops Matters Müller-Lierheim, Wolfgang G.K. Diagnostics (Basel) Review The chain length of hyaluronan (HA) determines its physical as well as its physiological properties. Results of clinical research on HA eye drops are not comparable without this parameter. In this article methods for the assessment of the average molecular weight of HA in eye drops and a terminology for molecular weight ranges are proposed. The classification of HA eye drops according to their zero shear viscosity and viscosity at 1000 s(−1) shear rate is presented. Based on the gradient of mucin MUC5AC concentration within the mucoaqueous layer of the tear film a hypothesis on the consequences of this gradient on the rheological properties of the tear film is provided. The mucoadhesive properties of HA and their dependence on chain length are explained. The ability of HA to bind to receptors on the ocular epithelial cells, and in particular the potential consequences of the interaction between HA and the receptor HARE, responsible for HA endocytosis by corneal epithelial cells is discussed. The physiological function of HA in the framework of ocular surface homeostasis and wound healing are outlined, and the influence of the chain length of HA on the clinical performance of HA eye drops is illustrated. The use of very high molecular weight HA (hylan A) eye drops as drug vehicle for the next generation of ophthalmic drugs with minimized side effects is proposed and its advantages elucidated. Consequences of the diagnosis and treatment of ocular surface disease are discussed. MDPI 2020-07-23 /pmc/articles/PMC7459843/ /pubmed/32717869 http://dx.doi.org/10.3390/diagnostics10080511 Text en © 2020 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Müller-Lierheim, Wolfgang G.K.
Why Chain Length of Hyaluronan in Eye Drops Matters
title Why Chain Length of Hyaluronan in Eye Drops Matters
title_full Why Chain Length of Hyaluronan in Eye Drops Matters
title_fullStr Why Chain Length of Hyaluronan in Eye Drops Matters
title_full_unstemmed Why Chain Length of Hyaluronan in Eye Drops Matters
title_short Why Chain Length of Hyaluronan in Eye Drops Matters
title_sort why chain length of hyaluronan in eye drops matters
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7459843/
https://www.ncbi.nlm.nih.gov/pubmed/32717869
http://dx.doi.org/10.3390/diagnostics10080511
work_keys_str_mv AT mullerlierheimwolfganggk whychainlengthofhyaluronanineyedropsmatters